MASSDEVICE ON CALL — French healthcare giant Sanofi (NYSE:SNY) is the last name on a short list of buyers for Bayer’s (PINK:BAYRY) blood glucose business, according to anonymous sources cited by the Wall Street Journal.
The deal, when completed, could be worth more than $1.5 billion, but the companies are still negotiating the final price and there is no guarantee that the deal will go through, according to the Journal.
Bayer has been attempting to offload its glucose devices business since earlier this year, but some analysts have questioned whether those efforts may be in vain.
Potential buyers that have already backed out include Johnson & Johnson (NYSE:JNJ), Abbott (NYSE:ABT) and Panasonic (NYSE:PC), the Journal reported.
Semprus lands $2.3M military grant
Limerick, Pa.-based surgical device maker Teleflex’s (NYSE:TFX) Semprus BioSciences subsidiary landed a $2.3 million grant from the U.S. Army’s Telemedicine & Advanced Technology Research Center in support of endotracheal tube technology.
Read more
Vascular Closure Systems closes 1st-in-human trial of Fastseal
Palo Alto, Calif.-based medical device maker Vascular Closure Systems successfully completed Phase I and Phase II of a 1st-in-human trial of its FastSeal bioabsorbable vascular access closure systems with a 100% success rate.
Read more
Stimulating the right nerve for treatment of overactive bladder
Uroplasty (NSDQ:UPI) unveiled results from a study of its tibial nerve stimulation system in treatment of overactive bladder, finding the percutaneous neuromodulation device was a more cost-effective treatment than sacral nerve stimulation.
Read more